BioCentury
ARTICLE | Clinical News

AZ01: Phase Ib data

October 31, 2011 7:00 AM UTC

A double-blind, placebo-controlled, multiple ascending-dose, European Phase Ib trial in 48 healthy volunteers showed that various doses of AZ01 given at 14- or 28-day intervals were well tolerated. Al...